Group 1 - The core issue is that Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for violations in annual report disclosures, highlighting significant flaws in the company's financial compliance [1][4] - The company has faced repeated accounting errors, including improper handling of sales returns and insufficient conditions for revenue recognition, leading to restatements of financial data [1][4] - The investigation represents a critical examination of the company's integrity and governance, emphasizing the importance for affected investors to protect their rights within the legal framework [1][4] Group 2 - Nanjing Pharmaceutical has announced a projected annual revenue of 120 million to 150 million yuan for 2025, a decline of approximately 43% to 54% compared to the previous year's revenue of 263 million yuan [2][4] - The company anticipates a net loss of 120 million to 160 million yuan, although this represents a reduction from the previous year's loss of 357 million yuan, indicating ongoing challenges in achieving profitability [2][4] - Factors contributing to the performance decline include intensified competition in the pharmaceutical industry and reduced demand for core products due to a decrease in flu cases, alongside a cautious approach to asset and credit impairment losses [2][5]

二、回购股份的进展情况 证券代码：688189 证券简称：南新制药 公告编号：2026-007 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,910,214股 | | 累计已回购股数占总股本比例 | 0.70% | | 累计已回购金额 | 16,138,029.08元 | | 实际回购价格区间 | 7.02元/股~8.92元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议 ...

格隆汇2月2日丨南新制药（维权）(688189.SH)公布，截至2026年1月31日，公司通过上海证券交易所交 易系统以集中竞价交易方式累计回购公司股份1,910,214股，占公司总股本的比例为0.70%，回购成交的 最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人民币16,138,029.08元（不含印花税、交易 佣金等交易费用）。 ...

Summary of Key Points Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has announced a share buyback program, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,910,214 shares, which represents 0.70% of its total share capital [1] - The highest price paid for the repurchased shares was 8.92 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the buyback was 16,138,029.08 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company expects a significant decline in revenue for the year 2025, projecting an operating income between 120 million to 150 million yuan, a decrease of 113.28 million to 143.28 million yuan compared to the previous year, representing a year-on-year decline of 43.03% to 54.42% [3] - The company anticipates a net loss attributable to shareholders of the parent company ranging from -160 million to -120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 55.17% to 66.38% [3] - The projected net loss attributable to shareholders after excluding non-recurring gains and losses is expected to be between -165 million to -125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 53.98% to 65.14% [4] Group 2 - The company reported a total profit loss of -388.64 million yuan for the year 2024, with a net loss attributable to shareholders of the parent company at -356.90 million yuan [6] - The earnings per share for the year 2024 were reported at -1.3007 yuan [7] Group 3 - The decline in performance is attributed to intensified market competition due to domestic pharmaceutical industry procurement policies and the introduction of similar competing products, along with a decrease in flu cases in the first three quarters of 2025, leading to reduced operating income and gross margin [8] - The company has maintained a high level of R&D investment to sustain its core competitiveness while implementing cost control measures, resulting in a significant decrease in sales and management expenses compared to the previous year [8] - Future strategies include adjusting marketing strategies, accelerating R&D progress, launching new products, optimizing product sales structure, and enhancing cost management to achieve sustainable and high-quality development [8]

Core Viewpoint - Company South New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the year 2025, primarily due to intensified market competition and reduced demand in the domestic pharmaceutical industry [1][2] Financial Performance - The projected revenue for 2025 is estimated to be between 120 million to 150 million yuan, representing a decrease of 113 million to 143 million yuan compared to the previous year, which is a year-on-year decline of 43.03% to 54.42% [1] - The expected net profit attributable to the parent company is projected to be a loss of 160 million to 120 million yuan, which is a reduction of 197 million to 237 million yuan compared to the previous year, reflecting a year-on-year decrease in losses of 55.17% to 66.38% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be a loss of 165 million to 125 million yuan, with a reduction in losses of 194 million to 234 million yuan compared to the previous year, indicating a year-on-year decrease in losses of 53.98% to 65.14% [1] Operational Factors - The decline in performance is attributed to intensified competition in the market due to domestic pharmaceutical procurement policies and the introduction of similar competing products [2] - The company has maintained a high level of R&D investment to sustain its core competitiveness despite the losses incurred [2] - Cost control measures have been implemented, resulting in a significant reduction in sales and management expenses compared to the previous year [2]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the fiscal year 2025, indicating ongoing financial challenges for the company [1] Financial Performance Summary - The company projects an annual revenue of between 120 million to 150 million yuan for 2025, which represents a decrease of 113.2848 million to 143.2848 million yuan compared to the previous year, translating to a year-on-year decline of 43.03% to 54.42% [1] - After excluding non-core business income and income lacking commercial substance, the expected revenue is between 119.9 million to 149.9 million yuan [1] - The anticipated net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.9036 million to 236.9036 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 55.17% to 66.38% [1] - The projected net profit attributable to the parent company, after excluding non-recurring gains and losses, is expected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.5310 million to 233.5310 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 53.98% to 65.14% [1]

Core Viewpoint - Nanjing Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the year 2025, primarily due to intensified market competition and reduced demand in the domestic pharmaceutical industry [1][2] Financial Performance - The company anticipates annual revenue for 2025 to be between 120 million to 150 million yuan, representing a decrease of 113 million to 143 million yuan compared to the previous year, which is a year-on-year decline of 43.03% to 54.42% [1] - The expected net profit attributable to the parent company is projected to be a loss of 160 million to 120 million yuan, reflecting a reduction in losses of 197 million to 237 million yuan compared to the previous year, which is a year-on-year decrease of 55.17% to 66.38% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be a loss of 165 million to 125 million yuan, with a reduction in losses of 194 million to 234 million yuan compared to the previous year, indicating a year-on-year decrease of 53.98% to 65.14% [1] Operational Factors - The decline in performance is attributed to intensified competition in the market due to domestic centralized procurement policies and the introduction of similar competing products [2] - The company has maintained a high level of R&D investment to sustain its core competitiveness despite the losses [2] - Cost control measures have been implemented, resulting in a significant reduction in sales and management expenses compared to the previous year [2]

Group 1 - The company Nanjing New Pharmaceutical is expected to report a net loss attributable to shareholders of the parent company for the year 2025, estimated between -160 million to -120 million yuan [1] - Compared to the same period last year, the loss is expected to decrease by approximately 197 million to 237 million yuan, representing a year-on-year reduction of 55.17% to 66.38% [1] - The main reasons for the performance change include intensified market competition due to domestic pharmaceutical industry procurement policies and the continuous launch of similar competing products, as well as a decrease in operating income and gross margin due to fewer flu cases in the first three quarters of 2025 [1] Group 2 - The company has maintained a high level of research and development investment to sustain its core competitiveness despite the reported losses [1] - During the reporting period, the company prudently recognized asset impairment losses and credit impairment losses [1]

证券代码：688189 证券简称：南新制药 公告编号：2026-006 湖南南新制药股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经湖南南新制药股份有限公司（以下简称"公司"）财务部门初步测算， 预计 2025 年年度实现营业收入 12,000.00 万元到 15,000.00 万元，与上年同期 相比，将减少 11,328.48 万元到 14,328.48 万元，同比减少 43.03%到 54.42%； 扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入为 11,990.00 万元到 14,990.00 万元。 3、预计 2025 年年度归属于母公司所有者扣除非经常性损益后的净利润为 -16,500.00 万元到-12,500.00 万元。与上年同期相比，亏损减少 19,353.10 万 元到亏损减少 23,353.10 万元，同比亏 ...